Real-world use of dotinurad and one-year prescription presence by kidney function in older adults
- 1Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
- 2Department of Infection Control and Infectious Disease Crisis Management, Mie University Graduate School of Medicine
- 3Department of Infection Control and Prevention, Mie University Hospital
Abstract
Evidence on dotinurad, a selective urate transporter 1 inhibitor, in older adults with reduced kidney function is limited. We conducted a retrospective cohort study using the Japan Medical Data Center elderly claims database from April 2021 to February 2023 to describe real-world dotinurad use, one-year prescription presence, and follow-up kidney function data among adults aged ≥ 75 years who underwent health check-ups with serum creatinine measurement. Among 782,897 eligible individuals, 81,674 (10.4%) received urate-lowering therapy. In the mutually exclusive baseline treatment classification, 840 patients (1.0%) were classified into the dotinurad group, whereas patients prescribed multiple urate-lowering therapies were classified separately as combination therapy users. In drug-specific counts, which included combination therapy, any dotinurad prescription was recorded in 1,094 patients, including 106 with eGFR ≤ 30 mL/min/1.73 m². Across the main eGFR categories from 15 to 30 to 60–90 mL/min/1.73 m², one-year prescription records for dotinurad were observed in 72.9–80.9% of drug-specific baseline users. Among 437 patients in the mutually exclusive dotinurad group with follow-up creatinine measurements, mean eGFR changed from 49.8 to 49.7 mL/min/1.73 m² over one year. These findings describe real-world dotinurad use in older adults, but comparative renal effects cannot be inferred.
Related
- FDA Accelerated Approval Disclosures on Direct-to-Consumer Prescription Drug Websites: Testing Presence, Prominence, and Wording
- Albuminuria, kidney function, and automatically quantified retinal vascular phenotypes in hospitalized adults with type 2 diabetes
- Prevalence, risk-factors and early prediction of impaired kidney function among indigenous adults in Odisha, India: A secondary analysis.
- Cerebral Hemodynamic Changes in Older Adults With Cognitive Complaints According to the Presence of Peripheral Artery Disease
- Effectiveness of a Physical Exercise Prescription Program in Primary Care to Improve Physical Fitness and Quality of Life in Adults Aged 65 Years and Older in a Rural Basic Health Area-Study Protocol for a Randomized Controlled Trial (PREFIS-AP).
BibTeX
@article{saiki2026realworld,
title = {{Real-world use of dotinurad and one-year prescription presence by kidney function in older adults}},
author = {Ryosuke Saiki and Masaki Tanabe and Tomohiro Murata and Daisuke Yamasaki and Shiho Ito and Kan Katayama and Kaoru Dohi},
journal = {Scientific Reports},
year = {2026},
month = aug,
doi = {10.1038/s41598-026-66267-w},
url = {https://doi.org/10.1038/s41598-026-66267-w},
note = {CC BY},
}
RIS
TY - JOUR
TI - Real-world use of dotinurad and one-year prescription presence by kidney function in older adults
AU - Ryosuke Saiki
AU - Masaki Tanabe
AU - Tomohiro Murata
AU - Daisuke Yamasaki
AU - Shiho Ito
AU - Kan Katayama
AU - Kaoru Dohi
PY - 2026
DA - 2026/08/01
JO - Scientific Reports
DO - 10.1038/s41598-026-66267-w
UR - https://doi.org/10.1038/s41598-026-66267-w
AB - Evidence on dotinurad, a selective urate transporter 1 inhibitor, in older adults with reduced kidney function is limited. We conducted a retrospective cohort study using the Japan Medical Data Center elderly claims database from April 2021 to February 2023 to describe real-world dotinurad use, one-year prescription presence, and follow-up kidney function data among adults aged ≥ 75 years who underwent health check-ups with serum creatinine measurement. Among 782,897 eligible individuals, 81,674 (10.4%) received urate-lowering therapy. In the mutually exclusive baseline treatment classification, 840 patients (1.0%) were classified into the dotinurad group, whereas patients prescribed multiple urate-lowering therapies were classified separately as combination therapy users. In drug-specific counts, which included combination therapy, any dotinurad prescription was recorded in 1,094 patients, including 106 with eGFR ≤ 30 mL/min/1.73 m². Across the main eGFR categories from 15 to 30 to 60–90 mL/min/1.73 m², one-year prescription records for dotinurad were observed in 72.9–80.9% of drug-specific baseline users. Among 437 patients in the mutually exclusive dotinurad group with follow-up creatinine measurements, mean eGFR changed from 49.8 to 49.7 mL/min/1.73 m² over one year. These findings describe real-world dotinurad use in older adults, but comparative renal effects cannot be inferred.
SN - 2045-2322
ER -